期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新辅助化疗对乳腺癌患者ER、PR、C-erbB-2、Ki-67表达的影响 被引量：1

下载PDF
导出
摘要 通过免疫组化法分别检测110例Ⅱ/Ⅲ期的乳腺癌病例在新辅助化疗前后乳腺癌组织中ER、PR、C-erbB-2、Ki-67的表达。结果发现,110例Ⅱ/Ⅲ期乳腺癌患者经2个周期的新辅助化疗后,ER、PR和C-erbB-2的表达均无明显变化(P>0.05);新辅助化疗后74例Ki-67由高表达变为低表达(P<0.01)。认为新辅助化疗可能部分通过抑制Ki-67的表达来抑制乳腺癌的增殖,但对ER、PR、C-erbB-2的表达化疗前后无显著差异。
作者 李荣萍 吕文静 任佳 张铁 韩猛 张莘 孙立 李东河 刘峰
机构地区 秦皇岛市第一医院 秦皇岛市肿瘤医院
出处 《山东医药》 CAS 北大核心 2009年第8期55-57,共3页 Shandong Medical Journal
关键词 乳腺癌 新辅助化疗 KI-67
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1陈灿铭,沈坤炜,沈镇宙.可手术乳腺癌系统性辅助化疗[J].实用临床医药杂志,2003,7(2):107-111. 被引量：12
  • 2Lo SS, Wang HC, Shyr YM. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy [ J ] ? J Surg oncol, 1994,57(2) :94-96.
  • 3Jain V, Landry M, Levine EA, et al. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma [J]. Am Surg, 1996,62(2):162-165.
  • 4费伯健,周士福,金留根,林奇.新辅助化疗对乳腺癌激素受体表达和状态的影响[J].南京医科大学学报（自然科学版）,2005,25(11):772-774. 被引量：18
  • 5Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of C-erbB-2 expression in breast cancer [J]. J Surg Oncol, 2002,79(4) :216-223.
  • 6Dagrda GP, Mezzlani A, Alasio L, et al. HER-2/neu assessment in primary chemotherapy treated breast carcinoma : no evidence of gene profile changing [ J ]. Breast Cancer Research and Treatment, 2003,80(2) :207-214.
  • 7毛杰,海健,舒衡平,唐利立,申正堂,邬玉辉,欧慧英.乳腺癌组织中survivin、c-erbB-2基因的表达与预后的关系[J].中国癌症杂志,2005,15(5):432-434. 被引量：8
  • 8Collecchi P, Baldini E, Giannessi P, et al. Primary chemotherapy in locally advanced breast cancer ( LABC ) : effects on tumour proliferative activity, bel-2 expression and the relationship between tumour regression and biological markers [ J]. Eur J Cancer, 1999, 34( 11 ) : 1701-1704.

二级参考文献38

  • 1阚秀.读WHO(2003)乳腺肿瘤组织学新分类[J].诊断病理学杂志,2004,11(3):135-137. 被引量：18
  • 2Carlson R W, Edge S B, Theriault R L. NCCN: Breast cancer[J]. Cancer Control, 2001, 8(6 Suppl 2) : 54.
  • 3Galea M H, Blamey R W, Elston C E, et al. The Nottingham prognostic index in primary breast cancer[J]. Breast Cancer Res Treat, 1992, 22: 207.
  • 4Nabholtz J M, Pienkowski T, Maekey J, et al. Phase Ⅲ trial comparing TAC with FAC in the adjuvant treatment of node positive breast cancer patients: interim analysis[J].ASCO, 2002.
  • 5Fisher B, Anderson S, Wolmark N, et al. Cheznotherapy with or without tamoxifen for patients with ER-negative breast cancer and negative nodes: Result from NSABP B-23[J]. J Clin Oneol, 2001, 19: 931.
  • 6Goldhirsch A, Glick J H, Gelber R D, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer[J]. J natl Cancer Inst 90, 1998, 19 (18): 3817.
  • 7Goldhirsch A, Gliek J H, Gelber R D, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer[J]. J Clin Oncol, 2001, 19(18): 3817.
  • 8National Institutes of Health Consensus Development Conference[J]. J Natl Cancer Inst Monogr, 2001, 30: 1.
  • 9Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxlfen in high-risk node negative breast cancer patients and a natural history follow-up study in lowrisk node negative patients: First results of Intergroup trial INT 0102[J]. Proc Am Soc Clin Oncol, 1998, 17: la.
  • 10Levine M, Bramwell V, Pritchard K, et al. Randomized trial of intensive cyelophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluomuraeil in premenopansal women with nodepositive breast cancer[J]. National Cancer Institute of Canada Clinical Trials Group, J Clin Oneol, 1998, 16: 2651.

共引文献31

同被引文献4

引证文献1

二级引证文献4

山东医药
2009年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部